Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Domatinostat - 4SC

Drug Profile

Domatinostat - 4SC

Alternative Names: 4SC-202

Latest Information Update: 17 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nycomed
  • Developer 4SC; Netherlands Cancer Institute
  • Class Antineoplastics; Benzamides; Pyrazoles; Pyrroles; Small molecules; Sulfones
  • Mechanism of Action BRD4 protein modulators; HDAC1 protein inhibitors; HDAC2 protein inhibitors; HDAC3 protein inhibitors; Lysine specific demethylase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Bladder cancer; Cancer; Colorectal cancer; Gastrointestinal cancer; Haematological malignancies; Malignant melanoma; Merkel cell carcinoma; Oesophageal cancer; Pancreatic cancer; Small cell lung cancer; Triple negative breast cancer

Most Recent Events

  • 26 Feb 2024 4SC completes phase-II MERKLIN2 trial in Merkel cell carcinoma (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Belgium, France, Netherlands, Spain, Italy and Germany (PO) (NCT04393753)
  • 31 Jul 2022 4SC and Vuja De Sciences enter into a material transfer and option agreement for domatinostat
  • 22 Feb 2022 Discontinued - Phase-I for Bladder cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Neoadjuvant therapy) in Netherlands (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top